$OCUL News
Last published 3d ago
- 3d agoOCULOcular Q3 2026 Results - OCULAR THERAPEUTIX INCEarnings Call TranscriptsGood morning and welcome to the Ocular Therapeutics Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer
- 3d agoOCULOCULAR Q3 2026 RESULTS - OCULAR THERAPEUTIX INCEarnings Call TranscriptsGood morning and welcome to the Ocular Therapeutics Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer
- 3d agoOCULOCULAR THERAPEUTIX, INC - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoOCULOcular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswireAXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on
- 6d agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina
- 6d agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical...
- 1w agoOCULOcular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026GlobeNewswireBEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that
- 2w agoOCULOcular Therapeutix™ to Participate in November Investor and Scientific ConferencesGlobeNewswireBEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced
- 3w agoOCULOcular Therapeutix – Piper Sandler Fireside Chat - OCULAR THERAPEUTIX INCEarnings Call TranscriptsAll right, maybe we could get started. My name is Biran Amin, I'm one of the biotech analysts here at Piper Sandler. We've got a fireside webinar with Ocular Therapeutics this afternoon. I'd like to welcome Dr. Praveen D
- 3w agoOCULCHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - OCULAR THERAPEUTIX INCEarnings Call TranscriptsFireside chat has started here, guys. Again, welcome. So we're shifting from gene therapy to wet AMD. And I'm proud to be joined by Dr. Praveen Dougal, Executive Chairman, President, and CEO of Ocular Therapeutics. In Fe
- 1mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina
- 1mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina
- 1mo agoOCULBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - OCULAR THERAPEUTIX INCEarnings Call TranscriptsAwesome. Thank you all for taking the time to join us today. For those unfamiliar, my name is Jack Allen. And for this session at the Baird Health Care Conference, we have the Ocular Therapeutics team and we have Praveen
- 1mo agoOCULBAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - OCULAR THERAPEUTIX INCEarnings Call TranscriptsAwesome. Thank you all for taking the time to join us today. For those unfamiliar, my name is Jack Allen. And for this session at the Baird Health Care Conference, we have the Ocular Therapeutics team and we have Praveen
- 1mo agoOCULOcular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMDGlobeNewswireConsistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission
- 2mo agoOCULOcular Therapeutix™ to Participate in September and October Investor and Scientific ConferencesGlobeNewswireBEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced
- 3mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina
- 3mo agoOCULOcular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business HighlightsGlobeNewswireOcular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient
- 4mo agoOCULOcular Therapeutix™ to Participate in July Scientific and Investor ConferencesGlobeNewswireBEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced
- 4mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina
- 4mo agoOCULOcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026GlobeNewswirePer May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients
- 5mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today
- 5mo agoOCULOcular Therapeutix™ to Participate in Clinical Trials at the Summit 2026GlobeNewswireBEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation
- 5mo agoOCULOcular Therapeutix™ to Host Investor Day on June 17, 2026GlobeNewswireIn addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight
- 6mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today
- 6mo agoOCULOcular Therapeutix™ Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswireEnrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD
- 6mo agoOCULOcular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMDGlobeNewswireSOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R
- 6mo agoOCULOcular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026GlobeNewswireBEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans
- 6mo agoOCULOcular Therapeutix™ to Participate in May Scientific and Investor ConferencesGlobeNewswireBEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation
- 6mo agoOCULOcular Therapeutix™ to Host Investor Day on June 17, 2026GlobeNewswireBEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host
- 7mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today
- 7mo agoOCULOcular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMDGlobeNewswireNew SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks and 46 weeks to ≥30
- 7mo agoOCULOcular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in AprilGlobeNewswireBEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation
- 8mo agoOCULOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has
- 8mo agoOCULOcular Therapeutix™ to Participate in March Investor ConferencesGlobeNewswireBEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the
- 8mo agoOCULOcular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss PresentationsGlobeNewswireOcular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM
- 8mo agoOCULOcular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMDGlobeNewswireFirst ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the
- 9mo agoOCULOcular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026GlobeNewswireOcular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular
- 9mo agoOCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has
- 9mo agoOCULOcular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewswireSOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1
- 9mo agoOCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has
- 9mo agoOCULOcular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial OfficerGlobeNewswireAccomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer,
- 11mo agoOCULOcular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMDGlobeNewswireOcular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2)
- 11mo agoOCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has
- 11mo agoOCULOcular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDRGlobeNewswireFirst patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary
- 1y agoOCULOcular Therapeutix™ to Participate in November and December Investor ConferencesGlobeNewswireBEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation
- 1y agoOCULOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has
- 1y agoOCULOcular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewswireRecent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target
- 1y agoOCULOcular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-RGlobeNewswireSOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA
- 1y agoOCULOcular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025GlobeNewswireBEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans